Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M G Brunstein

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Clinical Pharmacy and Therapeutics|May 15, 2001
Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine-glutamate interactionsM G Brunstein, P Belmonte-de-Abreu, D O Souza, et al.
International Clinical Psychopharmacology|July 19, 2001
Allopurinol augmentation for poorly responsive schizophreniaD R Lara, M G Brunstein, E S Ghisolfi, et al.
Neuroscience Letters|February 10, 2007
Increased serum adenosine deaminase activity in schizophrenic receiving antipsychotic treatmentM G Brunstein, E M Silveira, L S Chaves, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Clinical Pharmacy and Therapeutics|May 15, 2001
Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine-glutamate interactionsM G Brunstein, P Belmonte-de-Abreu, D O Souza, et al.
International Clinical Psychopharmacology|July 19, 2001
Allopurinol augmentation for poorly responsive schizophreniaD R Lara, M G Brunstein, E S Ghisolfi, et al.
Neuroscience Letters|February 10, 2007
Increased serum adenosine deaminase activity in schizophrenic receiving antipsychotic treatmentM G Brunstein, E M Silveira, L S Chaves, et al.
Pageof 1